KyungDong Pharm plans to strengthen its circulatory system product lineup by launching the high blood pressure/hyperlipidemia combination drug ‘Valtrio Tablet’ on December 1. ‘Valtrio Tablet’ is a three-drug combination drug that combines valsartan, an ARB component for the treatment of high blood pressure, amlodipine, a CCB component, and rosuvastatin, a hyperlipidemia treatment.

 

‘Valtrio Tablet’ is the first product for which KyungDong Pharm conducted phase 3 clinical trials and was approved after clinical trials conducted at 15 institutions, including Kangdong Kyunghee University Hospital, Samsung Seoul Hospital, Seoul National University Hospital, and Seoul St. Mary’s Hospital.

 

In a phase 3 clinical trial in which 175 patients with hypertension and dyslipidemia were divided into Valtrio administration group, ARB+statin administration group, and CCB+ARB administration group for 8 weeks, it was found to have excellent blood pressure lowering and lipid lowering effects.

 

KyungDong Pharm said, “Valtrio is a three-drug combination drug that can control high blood pressure and LDL-C with one pill, and we expect better treatment effects and higher medication compliance compared to two-drug combination drugs. It is more economical than administering each single drug in combination.”

Meanwhile, KyungDong Pharm already has a high market share in the valsartan market and the statin market. In particular, Valdipine, a valsartan/amlodipine combination drug, is showing excellent performance by ranking first in sales in the clinic market in 2019, and is actively expanding the market by strengthening its lineup with the launch of Valtrio and establishing a bridgehead for landing in general hospitals.

 

In the future, KyungDong Pharm is expected to expand its product line by continuing to focus on developing new products such as KDF1901, a three-drug combination drug for high blood pressure, and KDF1905, a two-drug combination drug for the urinary system.

♤ Product Information ♤

Product Name

Valtrio Tablet 5/80/10mg, 5/160/10mg, 10/160/10mg

Ingredient content

Amlodipine + valsartan + rosuvastatin (5/80/10mg, 5/160/10mg, 10/160/10mg)

Indications

This drug is only used in patients who need to take amlodipine/valsartan combination and rosuvastatin simultaneously.

Dosage and usage

Take this medicine 1 tablet once a day with water.

Reimbursement Prices

Valtrio tablets 5/80/10mg: KRW 1,260/tablet

Valtrio tablets 5/160/10mg: KRW 1,415/tablet

Valtrio tablets 10/160/10mg: KRW 1,656/tablet

Reimbursement Code

Valtrio Tablet 5/80/10mg: 648104570

Valtrio Tablet 5/160/10mg: 648104560

Valtrio Tablet 10/160/10mg: 648104550

Packaging unit

30 tablets/bottle

※ Please refer to the product manual for other details such as precautions for use.